Special Issues
Table of Content

Next-Generation Oncology: Unearthing and Validating Novel Therapeutic Targets

Submission Deadline: 31 July 2026 View: 1170 Submit to Special Issue

Guest Editor(s)

Dr. Shaoqiu Chen

Email: shaoqiu@hawaii.edu

Affiliation: Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA

Homepage:

Research Interests: Bioinformatics, Cancer biomarker, Cancer Immunotherapy


Dr. Hao Chi

Email: chihao@hawaii.edu

Affiliation: Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA

Homepage:

Research Interests: Multi-omics, machine learning, deep learning, tumor immunology


Summary

The landscape of oncology is rapidly evolving, driven by our ability to identify novel therapeutic targets with greater precision. This special issue is dedicated to the full spectrum of this discovery process. We invite contributions that begin with innovative computational and bioinformatic approaches for mining complex biological datasets to identify promising targets. The core of this issue will be the subsequent experimental validation, showcasing studies that confirm the functional importance of these targets in cancer progression and survival. We are particularly interested in manuscripts that successfully integrate both computational discovery and wet-lab validation, addressing the challenges inherent in moving a potential target from an in-silico prediction to a functionally verified entity. The goal is to create a collection of high-impact articles that not only present novel targets but also provide a roadmap for their thorough preclinical validation.


Keywords

Therapeutic Targets; Innovative Therapeutics; Preclinical Validation;Translational Research;multi-Omics

Published Papers


  • Open Access

    ARTICLE

    Tumour-Derived sEVs Promote Triple-Negative Breast Cancer Progression Associated with HAVCR2 Upregulation in Macrophages

    Jia Liu, Binqian Wang, Yannan Jin, Wenquan Chen, Ruohan Shi, Weijia Wang, Xiaojing Zhang, Yi Tan, Zhongran Man, Bo Hu, Lisen Zhu, Biao Zhang, Chongchan Bao, Gongsheng Jin
    Oncology Research, DOI:10.32604/or.2026.079137
    (This article belongs to the Special Issue: Next-Generation Oncology: Unearthing and Validating Novel Therapeutic Targets)
    Abstract Backgrounds: Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with a unique tumor microenvironment, and while Programmed cell death protein 1/Programmed cell death ligand 1 (PD-1/PD-L1) blockade represents a standard immunotherapy, most patients develop primary or acquired resistance, with few alternative immunotherapeutic targets currently available. Therefore, we aimed to identify potential immune checkpoint-related molecules involved in TNBC-macrophage crosstalk, clarify the underlying molecular mechanism mediated by small extracellular vesicles (sEVs), and provide a theoretical basis for the future development of novel immunotherapeutic targets against TNBC. Methods: Single-cell RNA-sequencing (scRNA-seq) datasets for various breast cancer… More >

  • Open Access

    ARTICLE

    SLC16A1 Activates the STAT3/SLC7A11 Pathway to Mediate Ferroptosis Resistance and Tumor Progression in Head and Neck Squamous Cell Carcinoma

    Chunhui Tian, Weipin Xie, Wen Li, Huaiyu Gu, Xuebao Liu, Busheng Tong, Yehai Liu, Huaiyuan Zong
    Oncology Research, Vol.34, No.5, 2026, DOI:10.32604/or.2026.077171
    (This article belongs to the Special Issue: Next-Generation Oncology: Unearthing and Validating Novel Therapeutic Targets)
    Abstract Background: In head and neck squamous cell carcinoma (HNSCC), solute carrier family 16 member 1 (SLC16A1) is associated with tumor advancement and reduced sensitivity to ferroptosis, yet the molecular basis of these effects remains unclear. This study seeks to uncover how SLC16A1 contributes to HNSCC tumorigenesis. Methods: To elucidate how SLC16A1 drives HNSCC progression via ferroptosis resistance, we performed RNA sequencing on SLC16A1-knockdown HNSCC cells and controls, followed by functional validation. We next systematically assessed the role of the candidate molecule solute carrier family 7 member 11 (SLC7A11) in HNSCC progression and resistance to ferroptosis… More >

    Graphic Abstract

    SLC16A1 Activates the STAT3/SLC7A11 Pathway to Mediate Ferroptosis Resistance and Tumor Progression in Head and Neck Squamous Cell Carcinoma

Share Link